Renin-Inhibitors Market Size, Share, Industry, Forecast and outlook (2024-2031)

Renin-Inhibitors Market is Segmented By Drug (TEKTURNA (aliskiren), TEKTURNA HCT (aliskiren/hydrochlorothiazide)), By Product Type(150mg/Tablet, 300mg/Tablet, Other), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis,  2023-2030.

Renin-Inhibitors Market Overview

Renin-Inhibitors Market is expected to grow at a CAGR of 6.7% during the forecast period (2023-2030). 166 pages report analyses the Renin-Inhibitors market shares, recent trends, competitive intelligence and future market outlook. Renin-Inhibitors usage in hypertension treatment is on the rise. Demand from pharmaceuticals & commercial infrastructure in ‘North America’ is booming. Competitive rivalry intensifies with Novartis, Noden Pharma DAC and others operating in the market.

Renin-Inhibitors are pharmaceutical drugs that inhibit the activity of renin, which is responsible for hydrolyzing angiotensinogen to angiotensin I, thereby reducing the formation of angiotensin II, which lowers blood pressure.

Renin-Inhibitors Market Scope

To Get a Free Sample Click here

Renin-Inhibitors Market Dynamics

Renin-Inhibitors Market is the growing demand for Renin-Inhibitors for high blood pressure.

The growing demand for renin-inhibitors for high blood pressure is expected to drive the market growth

Direct renin inhibitors prevent the enzyme renin from initiating a process that aids in blood pressure regulation. Due to which blood vessels relax and widen, blood flow more quickly through the vessels and lower blood pressure. Direct renin inhibitors, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin II receptor blockers (ARBs) narrow blood vessels. However, each type of medicine inhibits a different part of the process.

Direct renin inhibitors are used to treat hypertension. For instance, Aliskiren is a direct renin inhibitor that reduces plasma renin activity and inhibits the conversion of angiotensinogen to angiotensin I (thus decreasing angiotensin II) and thus disrupts the renin-angiotensin-aldosterone feedback loop.

Side effects associated with renin-inhibitors is expected to hamper the market growth

Aliskiren, a direct renin inhibitor, is an effective antihypertensive agent with side effects similar to ARBs (Angiotensin II receptor blockers). Still, there is no evidence of benefit in hard endpoint outcome trials. Because of the risk of worsening kidney function, hypotension, and hyperkalemia, aliskiren should not be used in patients with diabetes or CKD who are also taking ACE inhibitors or ARBs.

The common side effects are vomiting, nausea, diarrhea, hyperkalemia (increase in potassium levels in the blood), severe hypotension (low blood pressure), dizziness, headache, angioedema (accumulation of fluid cause swelling of the area below the skin or mucosa), tiredness, chest ache, rhabdomyolysis (muscle injury), toxic epidermolysis (severe skin reaction), hyponatremia (decreased sodium levels), renal calcifications, serum creatinine levels have risen, and anaphylactic shock (life-threatening allergic reactions). Hence, the side effects and limitations associated with renin-inhibitors are expected to hamper the market growth.

COVID-19 Impact Analysis

The pathogen that causes COVID-19, SARS-CoV-2, enters human cells via angiotensin-converting enzyme 2 (ACE2), which plays an important regulatory role in the renin-angiotensin system (RAS). And the widespread expression of ACE2 in many organ tissues may explain why COVID-19 is a systemic disease that can affect organ systems other than the lungs, such as the heart, gastrointestinal tract, and central nervous system. Despite conflicting evidence, experimental findings suggest that pharmacological RAS inhibition can increase ACE2 expression in organs such as the heart, intestine, kidney, or urogenital tract, although conflicting results exist.

The onset of the pandemic raised significant concerns based on mechanistic considerations that increased ACE2 expression could negatively affect the progression of COVID-19 by increasing the availability of the target receptors of SARS-CoV-2. These concerns were bolstered by discovering that severe COVID-19 courses occurred primarily in patients with comorbidities typically treated with ACE inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs). However, because of its anti-inflammatory properties, increased ACE2 expression may have beneficial effects in COVID-19. As a result, the net effect of RAS inhibitor-induced ACE2 upregulation on COVID-19 clinical outcome remains unknown.

Renin-Inhibitors Market Segment Analysis

By drug, the Aliskiren segment is expected to dominate the market growth

The increasing incidence of hypertension is expected to drive the market growth of this segment. For instance, hypertension affects an estimated 26 percent of the world's population (972 million people) globally, and the prevalence is expected to rise to 29 percent by 2025, owing largely to increases in economically developing countries. The high prevalence of hypertension imposes a significant public health burden.

Aliskiren is a renin antagonist.In the renin-angiotensin-aldosterone system, renin is the first enzyme that regulates blood pressure. It cleaves angiotensinogen to angiotensin I, converted to angiotensin II by angiotensin-converting enzyme (ACE). Aliskiren (Tekturna and Rasilez brand names) is the first in a class of drugs known as direct renin inhibitors. It treats essential (primary) hypertension. Aliskiren is used to treat high blood pressure either alone or with other medications (hypertension). The product is available in tablets.

Renin-Inhibitors Market Geographical Analysis

North America region is expected to hold the largest market share in the global renin-inhibitors market

The increasing prevalence of hypertension and the presence of key players in this region is expected to drive the market growth in this region.

For instance, according to CDC, In 2019, hypertension was a primary or contributing cause in more than 500,000 deaths in the United States. Approximately half of adults in the U.S (47 percent, or 116 million) have hypertension and are on hypertension medication. Only about one-quarter (24%) of adults with hypertension have their condition under control.

Hence, with the increasing prevalence of hypertension, the renin-inhibitors market is expected to grow in this region.

Renin-Inhibitors Market Competitive Landscape

With mergers, acquisitions, and drug approvals, the global renin-inhibitors market is moderately competitive. Some of the key players in the market are Novartis, Noden Pharma DAC, and others.

Noden Pharma DAC

Overview: Noden Pharma DAC is a global specialty pharmaceutical company focused on acquiring prescription medicines in international markets across many therapeutic areas. The company's resources are focused on acquiring and optimising existing medicines. The corporate headquarters are in Dublin, Ireland.

Product Portfolio: The company’s product tekturna is approved for the treatment of hypertension in adults and paediatric patients weighing 50 kg or more who are at least 6 years old and older.

Key Development: On May 4 2019, PDL BioPharma, Inc. launched aliskiren hemifumarate 150 mg and 300 mg tablets, an authorised generic of Tekturna. Tekturna's authorised generic has the same drug formulation. Prasco, LLC, d/b/a Prasco Laboratories, is carrying out the launch under an agreement with PDL's wholly owned subsidiary, Noden Pharma USA, Inc. ("Noden"). Noden will continue to manufacture and market prescription aliskiren products in the United States under the Tekturna and Tekturna HCT(aliskiren and hydrochlorothiazide) brands, and under the Rasilez and Rasilez HCT brands in international markets (collectively, the "Tekturna Products"). Tekturna HCT is not included in the authorised generic launch.